Novavax bosses cash out for $46 mil with COVID-19 vaccine trials still under way

By Jessica DiNapoli

The requested article has expired, and is no longer available. Any related articles, and user comments are shown below.

© Thomson Reuters 2021.

©2021 GPlusMedia Inc.

Login to comment

Cashing out on a 34 year old company which has yet to bring a vaccine to market. Not very encouraging!

2 ( +3 / -1 )

Rats jumping ship!!!

3 ( +4 / -1 )

They know if their vaccine is unsuccessful, or if the competitors' vaccines are so successful that no one buys Novavax, their company value will go back to $250M again. So get it while the getting is good.

Also, cashing out their gains before the incoming administration and Democrat congress vacate the favorable tax rates from the Tax Cuts and Jobs Act.

3 ( +3 / -0 )

Login to leave a comment

Facebook users

Use your Facebook account to login or register with JapanToday. By doing so, you will also receive an email inviting you to receive our news alerts.

Facebook Connect

Login with your JapanToday account

User registration

Articles, Offers & Useful Resources

A mix of what's trending on our other sites